XKH002
XKH002 is a recombinant humanized IgG4 monoclonal antibody against B7S1 that is independently developed Kanova Biopharma. XKH002 can specifically bind to B7S1 (also known as B7-H4) effectively block the inhibitory effects of B7S1 on T cell proliferation, activation, and related immune responses. XKH002 helps restore and enhance the body's anti-tumor immune response and has broad-spectrum anti-cancer potential. Animal tumor model studies have shown that XKH002 can enhance the inhibition of tumor growth when used in combination with chemotherapy drugs or IO drugs such as PD-1 antibodies.
XKH002 has received IND approval in both China and the US, and is the first B7S1 blocking antibody to enter the clinical development stage worldwide.
XKH002 patent applications have been submitted in several major countries, with patent granted in three countries, and the rest are in the substantive examination stage.
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com